Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More
Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More
PANACEA BIOTECH | ABBOTT INDIA | PANACEA BIOTECH/ ABBOTT INDIA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 8.9 | 47.1 | 18.8% | View Chart |
P/BV | x | 3.5 | 15.2 | 22.7% | View Chart |
Dividend Yield | % | 0.0 | 0.5 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
PANACEA BIOTECH Mar-19 |
ABBOTT INDIA Mar-19 |
PANACEA BIOTECH/ ABBOTT INDIA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 354 | 8,834 | 4.0% | |
Low | Rs | 138 | 5,458 | 2.5% | |
Sales per share (Unadj.) | Rs | 74.6 | 1,731.1 | 4.3% | |
Earnings per share (Unadj.) | Rs | 6.7 | 211.9 | 3.2% | |
Cash flow per share (Unadj.) | Rs | 15.5 | 219.9 | 7.0% | |
Dividends per share (Unadj.) | Rs | 0 | 65.00 | 0.0% | |
Dividend yield (eoy) | % | 0 | 0.9 | 0.0% | |
Book value per share (Unadj.) | Rs | 57.2 | 945.2 | 6.1% | |
Shares outstanding (eoy) | m | 61.25 | 21.25 | 288.2% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 3.3 | 4.1 | 79.9% | |
Avg P/E ratio | x | 36.8 | 33.7 | 109.2% | |
P/CF ratio (eoy) | x | 15.9 | 32.5 | 48.8% | |
Price / Book Value ratio | x | 4.3 | 7.6 | 56.9% | |
Dividend payout | % | 0 | 30.7 | 0.0% | |
Avg Mkt Cap | Rs m | 15,061 | 151,848 | 9.9% | |
No. of employees | `000 | 2.3 | 3.5 | 66.4% | |
Total wages/salary | Rs m | 1,471 | 4,356 | 33.8% | |
Avg. sales/employee | Rs Th | 1,973.6 | 10,555.5 | 18.7% | |
Avg. wages/employee | Rs Th | 635.6 | 1,249.9 | 50.9% | |
Avg. net profit/employee | Rs Th | 176.8 | 1,292.2 | 13.7% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 4,567 | 36,786 | 12.4% | |
Other income | Rs m | 45 | 1,133 | 4.0% | |
Total revenues | Rs m | 4,612 | 37,919 | 12.2% | |
Gross profit | Rs m | 2,030 | 6,047 | 33.6% | |
Depreciation | Rs m | 540 | 169 | 319.1% | |
Interest | Rs m | 1,048 | 23 | 4,659.1% | |
Profit before tax | Rs m | 486 | 6,989 | 7.0% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 77 | 2,485 | 3.1% | |
Profit after tax | Rs m | 409 | 4,503 | 9.1% | |
Gross profit margin | % | 44.4 | 16.4 | 270.3% | |
Effective tax rate | % | 15.9 | 35.6 | 44.6% | |
Net profit margin | % | 9.0 | 12.2 | 73.2% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 2,415 | 27,610 | 8.7% | |
Current liabilities | Rs m | 9,077 | 8,569 | 105.9% | |
Net working cap to sales | % | -145.9 | 51.8 | -281.9% | |
Current ratio | x | 0.3 | 3.2 | 8.3% | |
Inventory Days | Days | 65 | 60 | 108.1% | |
Debtors Days | Days | 71 | 27 | 258.8% | |
Net fixed assets | Rs m | 8,333 | 1,057 | 788.5% | |
Share capital | Rs m | 61 | 213 | 28.8% | |
"Free" reserves | Rs m | 3,443 | 19,873 | 17.3% | |
Net worth | Rs m | 3,504 | 20,086 | 17.4% | |
Long term debt | Rs m | 461 | 0 | - | |
Total assets | Rs m | 13,755 | 29,409 | 46.8% | |
Interest coverage | x | 1.5 | 311.6 | 0.5% | |
Debt to equity ratio | x | 0.1 | 0 | - | |
Sales to assets ratio | x | 0.3 | 1.3 | 26.5% | |
Return on assets | % | 10.6 | 15.4 | 68.8% | |
Return on equity | % | 11.7 | 22.4 | 52.1% | |
Return on capital | % | 38.7 | 34.9 | 110.9% | |
Exports to sales | % | 20.9 | 0 | - | |
Imports to sales | % | 8.1 | 0 | - | |
Exports (fob) | Rs m | 954 | NA | - | |
Imports (cif) | Rs m | 372 | NA | - | |
Fx inflow | Rs m | 1,203 | 369 | 326.1% | |
Fx outflow | Rs m | 467 | 4,918 | 9.5% | |
Net fx | Rs m | 736 | -4,549 | -16.2% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 1,049 | 4,991 | 21.0% | |
From Investments | Rs m | -54 | -2,570 | 2.1% | |
From Financial Activity | Rs m | -1,011 | -1,428 | 70.8% | |
Net Cashflow | Rs m | -20 | 993 | -2.0% |
Indian Promoters | % | 74.5 | 0.0 | - | |
Foreign collaborators | % | 0.0 | 75.0 | - | |
Indian inst/Mut Fund | % | 0.6 | 7.9 | 7.6% | |
FIIs | % | 1.3 | 0.1 | 1,300.0% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 23.6 | 17.1 | 138.0% | |
Shareholders | 10,259 | 18,270 | 56.2% | ||
Pledged promoter(s) holding | % | 35.1 | 0.0 | - |
Compare PANACEA BIOTECH With: PROCTER & GAMBLE HEALTH STERLING BIOTECH ASTRAZENECA PHARMA AUROBINDO PHARMA IPCA LABS
Compare PANACEA BIOTECH With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
Indian share markets witnessed a sharp sell-off today and ended deep in the red.
For the quarter ended December 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (down 5.1% YoY). Sales on the other hand came in at Rs 11 bn (up 1.6% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
For the quarter ended June 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 54.2% YoY). Sales on the other hand came in at Rs 11 bn (up 6.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
For the quarter ended March 2020, ABBOTT INDIA has posted a net profit of Rs 1 bn (down 2.0% YoY). Sales on the other hand came in at Rs 10 bn (up 6.1% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
For the quarter ended December 2019, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 59.5% YoY). Sales on the other hand came in at Rs 11 bn (up 13.8% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
For the quarter ended June 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 41.9% YoY). Sales on the other hand came in at Rs 10 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
More Views on NewsLast time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.
A look at what India's top equity mutual funds bought and sold in January 2021.
Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.
More